Latest News & Insights
Stay Up to Date with Our Community
Featured
June 24, 2025
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data...
Loading...
June 24, 2025
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2...
June 11, 2025
Capsida is initiating the Phase 1/2 study for CAP-003, with the...
May 14, 2025
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance...
April 28, 2025
Capsida will also present data from its potential best-in-class programs for...
April 3, 2025
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration...
March 25, 2025
Neuron23 today announced the publication of a manuscript in the Proceedings of...
March 24, 2025
Data from the Phase 1 healthy volunteer study of NEU-411 will...
March 17, 2025
Financing led by funds managed by Blue Owl Capital; Senior Managing...
March 3, 2025
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in...